文献速递皮肤肿瘤

他汀类药物或可降低溃疡性原发性黑色素瘤复发风险

Statins may reduce disease recurrence in patients with ulcerated primary melanoma.
PubMed 文献 · Br J Dermatol · 2020-04-05

在澳大利亚昆士兰前瞻性随访2010–2014年确诊的700例T1b–T4b局限性黑色素瘤患者,评估诊断前长期使用他汀与复发的关系。

核心结论

  • 诊断前开始的他汀使用可能与黑色素瘤复发风险降低相关,尤其在男性和溃疡性肿瘤患者中。

研究设计与样本

  • 前瞻性队列研究,纳入2010–2014年澳大利亚昆士兰新诊断的700例T1b–T4b局限性黑色素瘤患者。
  • 采用Cox回归分析长期他汀使用与黑色素瘤复发的关联,并按性别和溃疡情况分层。

主要发现

  • 700例患者中94例(13%)在2年内出现黑色素瘤复发。

临床怎么用

  • 对于高危黑色素瘤患者,尤其男性和溃疡性肿瘤者,他汀使用可能有助于改善预后,但需临床试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Statins may restrict the cellular functions required for melanoma growth and metastasis. OBJECTIVES: To determine whether long-term statin use commenced before diagnosis of a primary melanoma is associated with reduced risk of melanoma recurrence. METHODS: We prospectively followed a cohort of patients newly diagnosed between 2010 and 2014 with localized tumour-stage T1b to T4b melanoma in Queensland, Australia. We used Cox regression analyses to examine associations between long-term statin use and melanoma recurrence for the entire cohort, and then separately by sex and by presence of ulceration, due to evidence of effect modification. RESULTS: Among 700 patients diagnosed with stage T1b to T4b primary melanoma (mean age 62 years, 59% male, 28% with ulcerated tumours), 94 patients (13%) developed melanoma recurrence within 2 years. Long-term statin users (n = 204, 29%) had a significantly lower risk of disease recurrence than nonusers [adjusted hazard ratio (HRadj ) 0·55, 95% confidence Interval (CI) 0·32-0·97] regardless of statin subtype or potency. Compared with nonusers of statins, risk of recurrence was significantly decreased in male statin users (HRadj 0·39, 95% CI 0·19-0·79) but not in female statin users (HRadj 0·82, 95% CI 0·29-2·27) and in statin users with ulcerated (HRadj 0·17, 95% CI 0·05-0·52) but not nonulcerated (HRadj 0·91, 95% CI 0·46-1·81) primary melanoma. CONCLUSIONS: Statins commenced before melanoma diagnosis may reduce the risk of melanoma recurrence, especially in men and in those with ulcerated tumours. Clinical trial evaluation of the potential role of statins in improving the prognosis of high-risk melanoma is warranted.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. von Schuckmann LA, Khosrotehrani K, Ghiasvand R, et al. Statins may reduce disease recurrence in patients with ulcerated primary melanoma. Br J Dermatol. 2020. PMID: 32133622. doi:10.1111/bjd.19012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。